PharmiWeb.com - Global Pharma News & Resources
07-Jan-2019

ReNeuron signs exosome collaboration

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a collaboration agreement with a US-based biopharmaceutical company to explore the use of the Company’s exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy.

In the collaboration, ReNeuron will use its proprietary exosomes as well as sequence-based know-how and the US-based biopharmaceutical company will provide its expertise in the field of synthetic oligonucleotides to optimise their loading into exosomes.  

If the initial feasibility stage of the collaboration is successful, candidates with suitable pharmaceutical properties will be taken into the next part of the collaboration which will evaluate pre-clinical safety and potential efficacy.

During the initial feasibility stage there are no cash payments between the parties. On successful completion of the feasibility stage, it is anticipated that a product cross-licensing agreement will be signed by the parties ahead of the pre-clinical and clinical development of the therapeutic candidates.

Commenting on the agreement, Olav Hellebø, Chief Executive Officer of ReNeuron, said:

“Exosomes are biological nanoparticles ideally suited to the delivery of nucleic acid-based therapeutics due to their natural occurrence and abundance, their ability to protect their cargo from degradation and their potential for favourable bio-distribution. We are delighted to be collaborating with a biopharmaceutical company that has considerable experience in the development of novel oligonucleotide-based therapeutics.”

Editor Details

Last Updated: 07-Jan-2019